Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M R Middleton

Showing results (11-20 of 54) with videos related to

Pageof 6
Sort By:
British Journal of Cancer|January 7, 2012
Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumoursE Dean, M R Middleton, T Pwint, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2015
Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancerJ Bendell, E M O'Reilly, M R Middleton, et al.
Melanoma Research|April 4, 2002
Effect of temozolomide on central nervous system relapse in patients with advanced melanomaM J Paul, Y Summers, A H Calvert, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|May 24, 2012
Sentinel node status predicts survival in thick melanomas: the Oxford perspectiveM G Rughani, M C Swan, T S Adams, et al.
Ultrasonics|March 30, 2004
High-intensity focused ultrasound for the treatment of liver tumoursJ E Kennedy, F Wu, G R ter Haar, et al.
British Journal of Cancer|July 16, 2009
Societal preference values for advanced melanoma health states in the United Kingdom and AustraliaK M Beusterien, S M Szabo, S Kotapati, et al.
British Journal of Cancer|April 28, 2012
Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trialJ Cummings, M Zweifel, N Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2003
Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanomaS Danson, P Lorigan, A Arance, et al.
The British Journal of Surgery|February 14, 2012
Role of positron emission tomography-computed tomography in predicting survival after neoadjuvant chemotherapy and surgery for oesophageal adenocarcinomaR S Gillies, M R Middleton, C Han, et al.
International Journal of Cancer|January 11, 2000
O(6)-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenograftsM R Middleton, J Kelly, N Thatcher, et al.
Pageof 6

Showing results (11-20 of 54) with videos related to

Sort By:
Pageof 6
British Journal of Cancer|January 7, 2012
Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumoursE Dean, M R Middleton, T Pwint, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2015
Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancerJ Bendell, E M O'Reilly, M R Middleton, et al.
Melanoma Research|April 4, 2002
Effect of temozolomide on central nervous system relapse in patients with advanced melanomaM J Paul, Y Summers, A H Calvert, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|May 24, 2012
Sentinel node status predicts survival in thick melanomas: the Oxford perspectiveM G Rughani, M C Swan, T S Adams, et al.
Ultrasonics|March 30, 2004
High-intensity focused ultrasound for the treatment of liver tumoursJ E Kennedy, F Wu, G R ter Haar, et al.
British Journal of Cancer|July 16, 2009
Societal preference values for advanced melanoma health states in the United Kingdom and AustraliaK M Beusterien, S M Szabo, S Kotapati, et al.
British Journal of Cancer|April 28, 2012
Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trialJ Cummings, M Zweifel, N Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2003
Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanomaS Danson, P Lorigan, A Arance, et al.
The British Journal of Surgery|February 14, 2012
Role of positron emission tomography-computed tomography in predicting survival after neoadjuvant chemotherapy and surgery for oesophageal adenocarcinomaR S Gillies, M R Middleton, C Han, et al.
International Journal of Cancer|January 11, 2000
O(6)-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenograftsM R Middleton, J Kelly, N Thatcher, et al.
Pageof 6